Varda Completes $250 Million Series D with $1.6 Billion Valuation

Varda Space Industries, an orbital pharmaceutical company, announced the completion of $250 million in Series D financing, with a post-money valuation of $1.6 billion, bringing its total funding to $598 million. The funds will be used to increase the production of return capsules, expand pharmaceutical collaborations, and advance the first space-manufactured drugs for Earth patients.

This round was led by Lux Capital and Natural Capital, with participation from Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step, and Also Capital. Delian Asparouhov, co-founder, president, and partner at Founders Fund, stated that Lux secured this round early this year, and the team subsequently expanded the scale to approximately $250 million. He recalled that in 2014, when he was raising funds for his first company, Lux was the only institution that invited him to the full investment committee but rejected him for being 'not ambitious enough'; now, the 'space pharmaceutical factory' has passed the same threshold.

Varda was founded around 2021 by former SpaceX engineer and current CEO Will Bruey and Asparouhov, headquartered in El Segundo, California. Since 2023, it has executed six orbital missions using its gum-like W series free-flying return capsules, successfully re-entering all but the fourth mission. The company plans to send two capsules into space for the first time on Thursday, using SpaceX's Falcon 9 in a shared mission, Transporter-18, corresponding to W-8 and W-9: W-8 will carry re-entry temperature sensors, and the heat protection materials will be included in U.S. military research. The current capsule re-entry speed is about 25 Mach, with the next generation planned for 2030.

The customer base remains biased towards government and defense. Bruey stated that about 70% of payload customers next year will come from the government, with the rest from commercial pharmaceuticals, and expects this ratio to reverse by 2032. The capsules also handle semiconductor microgravity processing and national security customers needing hypersonic re-entry data; the Pentagon's "Iron Dome" related re-entry needs have also been publicly mentioned. The company claims to have booked about 28 different capacity launches from 2027 to 2029 to reduce dependence on a single rocket flight. Over the next two years, it also plans more than ten re-entries, with existing vehicles capable of bringing back about 50 kilograms of active pharmaceutical ingredients, with some pipelines nearing a quarterly batch.

Pharmaceutical organizations are synchronously filling positions. In August, former Pfizer R&D executive Mikael Dolsten was appointed to the board; about 18% of the approximately 275 employees have pharmaceutical backgrounds. Bruey has set the goal of "getting microgravity formulations into human clinical trials by the turn of the decade" as the company's biggest milestone. Public information also mentions that United Therapeutics has invested in developing microgravity formulations for rare lung diseases, and Varda has rented a former Mattel factory in El Segundo to expand spacecraft production. The use of funds has been clearly stated: to increase mission frequency, deepen pharmaceutical collaborations, and approach the first space-manufactured and usable drug.

In market mechanisms, this is an event-driven primary market increase, not a secondary trading market. Buyers include Lux, Natural Capital, and existing shareholders Founders Fund, Khosla, etc., investing money into return capsule capacity, launch bookings, and pharmaceutical laboratories, rather than buying shares of already listed pharmaceutical companies. The seller is the company's diluted equity, exchanged for combining "re-entry as military data and microgravity as drug crystal types" onto the same hardware. The immediate beneficiaries are those who can sell re-entry experiments and government payloads, as well as pharmaceutical partners needing new crystal types; the pressure is on traditional formulation capacities still priced according to ground crystallization processes and space station projects that can only sell single scientific experiments without bulk material recovery. The flow of funds is clear: from deep tech and life science funds into the capsule manufacturing line and orbital pharmaceutical slots in El Segundo.

The company reports a total funding of $598 million and a valuation of $1.6 billion; industry reports indicate this round's amount is between $250 million and $251 million, with the previous round being $187 million, bringing the total to about $329 million at that time. The publicly stated employee count is approximately 275.

Source: Public Information